Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
Recent Articles
RECENT ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
